It remains an unanswered question from the clinical trials whether the positive effects of SGLT2 inhibitors on heart failure occur predominantly in heart failure with a preserved ejection fraction (HFpEF) or heart failure with a reduced ejection fraction (HFrEF). This evidence concerns the gene SLC5A2 and heart failure.